These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22764764)

  • 1. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
    Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
    Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib for the treatment of HER2-positive early stage breast cancer.
    Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib Graduates to I-SPY 3.
    Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
    Seyhan AA; Varadarajan U; Choe S; Liu Y; McGraw J; Woods M; Murray S; Eckert A; Liu W; Ryan TE
    Mol Biosyst; 2011 Jun; 7(6):1974-89. PubMed ID: 21487605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
    Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.